BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37302574)

  • 1. Anti-gp210-positive primary biliary cholangitis: The dilemma of clinical treatment and emerging mechanisms.
    Wang X; Yang Z; Ran Y; Li L; Wang B; Zhou L
    Ann Hepatol; 2023; 28(5):101121. PubMed ID: 37302574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of autoantibodies in the clinical management of primary biliary cholangitis.
    Rigopoulou EI; Bogdanos DP
    World J Gastroenterol; 2023 Mar; 29(12):1795-1810. PubMed ID: 37032725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of antibodies to gp210 among patients with primary biliary cholangitis in Northeast China.
    Chen Q; Zhong R; Dong K; Wang Y; Kui Y; Ma B; Wen X; Jin Q
    Dig Liver Dis; 2022 Aug; 54(8):1094-1100. PubMed ID: 34789400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Anti-Sp100 and anti-Gp210 in the diagnosis of primary biliary cirrhosis in patients with autoimmune cholangitis].
    Romero Gómez M; Wichmann I; Otero Fernández MA; Suárez García E; Grande L; Núñez J; Nevado Santos M; Castro Fernández M
    Gastroenterol Hepatol; 1999 Jan; 22(1):11-3. PubMed ID: 10089705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical performance of AMA-M2, anti-gp210 and anti-sp100 antibody levels in primary biliary cholangitis: When detected by multiplex bead-based flow fluorescent immunoassay.
    Wang Z; Li Y; Ren L; Li Y; Xu T; Li W; Gao W; Sun G; Liu M
    Immun Inflamm Dis; 2024 Jan; 12(1):e1161. PubMed ID: 38270327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis.
    Haldar D; Janmohamed A; Plant T; Davidson M; Norman H; Russell E; Serevina O; Chung K; Qamar K; Gunson B; Hansen B; Richter A; Trivedi PJ; Hirschfield GM
    Liver Int; 2021 Mar; 41(3):535-544. PubMed ID: 33022821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presence of anti-gp210 or anti-sp100 antibodies in AMA-positive patients may help support a diagnosis of primary biliary cholangitis.
    Jaskowski TD; Nandakumar V; Novis CL; Palmer M; Tebo AE
    Clin Chim Acta; 2023 Feb; 540():117219. PubMed ID: 36610465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluctuations of antimitochondrial antibodies and anti-gp210 antibody in a patient with primary biliary cholangitis and Sjögren syndrome with subsequent autoimmune hemolytic anemia: A case report.
    Zhao DT; Liu YM; Han Y; Zhang HP; Zhao Y; Yan HP
    Medicine (Baltimore); 2020 Jan; 99(3):e18856. PubMed ID: 32011506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antinuclear autoantibodies Sp100 and gp210 persist after orthotopic liver transplantation in patients with primary biliary cirrhosis.
    Luettig B; Boeker KH; Schoessler W; Will H; Loges S; Schmidt E; Worman HJ; Gershwin ME; Manns MP
    J Hepatol; 1998 May; 28(5):824-8. PubMed ID: 9625318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210.
    Yang F; Yang Y; Wang Q; Wang Z; Miao Q; Xiao X; Wei Y; Bian Z; Sheng L; Chen X; Qiu D; Fang J; Tang R; Gershwin ME; Ma X
    Aliment Pharmacol Ther; 2017 Mar; 45(5):733-743. PubMed ID: 28083929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoimmune Markers in Primary Biliary Cholangitis.
    Shah SK; Bowlus CL
    Clin Liver Dis; 2024 Feb; 28(1):93-101. PubMed ID: 37945165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of primary biliary cholangitis with ursodeoxycholic acid, prednisolone and immunosuppressants in patients not responding to ursodeoxycholic acid alone and the prognostic indicators.
    Qian JD; Yao TT; Wang Y; Wang GQ
    Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):874-884. PubMed ID: 32305248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary biliary cholangitis with normal alkaline phosphatase: A neglected clinical entity challenging current guidelines.
    Terziroli Beretta-Piccoli B; Stirnimann G; Mertens J; Semela D; Zen Y; Mazzucchelli L; Voreck A; Kolbus N; Merlo E; Di Bartolomeo C; Messina P; Cerny A; Costantini S; Vergani D; Mieli-Vergani G;
    J Autoimmun; 2021 Jan; 116():102578. PubMed ID: 33229138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [How to understand the clinical significance of autoantibodies in primary biliary cholangitis].
    Yan HP; Zhang HP; Chen XX
    Zhonghua Gan Zang Bing Za Zhi; 2017 Nov; 25(11):810-815. PubMed ID: 29325273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoantibodies against a 210 kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis.
    Itoh S; Ichida T; Yoshida T; Hayakawa A; Uchida M; Tashiro-Itoh T; Matsuda Y; Ishihara K; Asakura H
    J Gastroenterol Hepatol; 1998 Mar; 13(3):257-65. PubMed ID: 9570238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study of clinical characteristics in patients with gp210 antibody-positive primary biliary cholangitis].
    Huang CY; Liu YM; Liu H; Xu B; Yan HP; Zhang HP; Liao HY; Zhang XD; Zhao J; Li WJ; Duan ZP
    Zhonghua Gan Zang Bing Za Zhi; 2022 Apr; 30(4):419-425. PubMed ID: 35545568
    [No Abstract]   [Full Text] [Related]  

  • 17. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis.
    Nakamura M; Shimizu-Yoshida Y; Takii Y; Komori A; Yokoyama T; Ueki T; Daikoku M; Yano K; Matsumoto T; Migita K; Yatsuhashi H; Ito M; Masaki N; Adachi H; Watanabe Y; Nakamura Y; Saoshiro T; Sodeyama T; Koga M; Shimoda S; Ishibashi H
    J Hepatol; 2005 Mar; 42(3):386-92. PubMed ID: 15710222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Primary biliary cholangitis].
    Soret PA; Chazouillères O; Corpechot C
    Rev Prat; 2021 Oct; 71(8):885-891. PubMed ID: 35147347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased expression of nuclear envelope gp210 antigen in small bile ducts in primary biliary cirrhosis.
    Nakamura M; Takii Y; Ito M; Komori A; Yokoyama T; Shimizu-Yoshida Y; Koyabu M; Matsuyama M; Mori T; Kamihira T; Daikoku M; Migita K; Yatsuhashi H; Nozaki N; Shimoda S; Ishibashi H
    J Autoimmun; 2006 Mar; 26(2):138-45. PubMed ID: 16337775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Prognostic Utility of Gp210 Antibody-Positive Rate in Primary Biliary Cholangitis: A Meta-Analysis.
    Huang C; Han W; Wang C; Liu Y; Chen Y; Duan Z
    Dis Markers; 2019; 2019():9121207. PubMed ID: 31737133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.